FUSN Fusion Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FUSN

Price (delayed)

$4.765

Market cap

$345.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.63

Enterprise value

$369.54M

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the ...

Highlights
The EPS has grown by 16% from the previous quarter and by 12% YoY
The gross profit has grown by 15% YoY
Fusion Pharmaceuticals's net income has decreased by 14% YoY but it has increased by 7% QoQ
Fusion Pharmaceuticals's equity has decreased by 7% QoQ but it has increased by 2.9% YoY
Fusion Pharmaceuticals's debt has increased by 30% YoY and by 4% from the previous quarter
The quick ratio has declined by 29% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://fusionpharma.com
Peers: OMGA

Key stats

What are the main financial stats of FUSN
Market
Shares outstanding
72.41M
Market cap
$345.01M
Enterprise value
$369.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.74
Price to sales (P/S)
149.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
167.36
Earnings
Revenue
$2.21M
EBIT
-$86.55M
EBITDA
-$83.36M
Free cash flow
-$86.58M
Per share
EPS
-$1.63
Free cash flow per share
-$1.25
Book value per share
$2.73
Revenue per share
$0.03
TBVPS
$3.67
Balance sheet
Total assets
$253.38M
Total liabilities
$64.91M
Debt
$52.63M
Equity
$188.47M
Working capital
$185.79M
Liquidity
Debt to equity
0.28
Current ratio
11.63
Quick ratio
11.03
Net debt/EBITDA
-0.29
Margins
EBITDA margin
-3,775.5%
Gross margin
100%
Net margin
-4,136.5%
Operating margin
-4,319.5%
Efficiency
Return on assets
-36.3%
Return on equity
-48.4%
Return on invested capital
-35.6%
Return on capital employed
-36.7%
Return on sales
-3,920%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FUSN stock price

How has the Fusion Pharmaceuticals stock price performed over time
Intraday
0.53%
1 week
-0.31%
1 month
18.24%
1 year
120.6%
YTD
51.27%
QTD
83.27%

Financial performance

How have Fusion Pharmaceuticals's revenue and profit performed over time
Revenue
$2.21M
Gross profit
$2.21M
Operating income
-$95.37M
Net income
-$91.34M
Gross margin
100%
Net margin
-4,136.5%
Fusion Pharmaceuticals's operating margin has soared by 84% from the previous quarter
Fusion Pharmaceuticals's net margin has soared by 84% from the previous quarter
The operating income has contracted by 17% YoY but it has grown by 4.4% from the previous quarter
The gross profit has grown by 15% YoY

Growth

What is Fusion Pharmaceuticals's growth rate over time

Valuation

What is Fusion Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.74
P/S
149.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
167.36
The EPS has grown by 16% from the previous quarter and by 12% YoY
The P/B is 58% higher than the last 4 quarters average of 1.1
Fusion Pharmaceuticals's equity has decreased by 7% QoQ but it has increased by 2.9% YoY
The P/S is 52% below the last 4 quarters average of 310.2
FUSN's revenue is up by 15% YoY

Efficiency

How efficient is Fusion Pharmaceuticals business performance
The ROS has soared by 85% from the previous quarter and by 8% YoY
FUSN's return on equity is down by 25% year-on-year but it is up by 8% since the previous quarter
The return on invested capital has increased by 24% year-on-year and by 18% since the previous quarter
FUSN's ROA is up by 8% QoQ but it is down by 8% YoY

Dividends

What is FUSN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FUSN.

Financial health

How did Fusion Pharmaceuticals financials performed over time
The quick ratio has declined by 29% year-on-year and by 5% since the previous quarter
Fusion Pharmaceuticals's current ratio has decreased by 28% YoY and by 4.4% from the previous quarter
Fusion Pharmaceuticals's debt is 72% less than its equity
Fusion Pharmaceuticals's debt has increased by 30% YoY and by 4% from the previous quarter
FUSN's debt to equity is up by 27% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.